Result:Very Good· Market: Down#Turnaround#Base effect
| Metric | Value (₹ Cr) | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue | 46.22 | 30.5% | 546.4% |
| Total Income | 46.29 | 30.3% | 546.0% |
| Expenditure | 43.45 | 27.4% | 466.8% |
| PBT | 2.84 | 100.0% | 668.1% |
| Net Profit | 2.12 | 99.6% | 524.7% |
| OPM | 6.04% | 2.26pp | 13.21pp |
| NPM | 4.59% | 1.60pp | 11.57pp |
| EPS | 0.90 | 100.0% | 328.6% |
Pharma manufacturer swung from a loss to a solid net profit with revenue up sharply YoY, but the prior-year base was extremely depressed (₹7.15 Cr revenue), so it's capped just into very_good rather than higher.
Informational and educational content only. Not investment advice.